

Dionysis Nikolopoulos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7130704/publications.pdf>

Version: 2024-02-01

17
papers

404
citations

1051969

10
h-index

993246

17
g-index

17
all docs

17
docs citations

17
times ranked

508
citing authors

#	ARTICLE	IF	CITATIONS
1	First Diagnosis of Systemic Lupus Erythematosus in Hospitalized Patients: Clinical Phenotypes and Pitfalls for the Non-Specialist. <i>American Journal of Medicine</i> , 2022, 135, 244-253.e3.	0.6	6
2	Tailored treatment strategies and future directions in systemic lupus erythematosus. <i>Rheumatology International</i> , 2022, 42, 1307-1319.	1.5	5
3	Demyelinating Syndromes in Systemic Lupus Erythematosus: Data From the "Attikon" Lupus Cohort. <i>Frontiers in Neurology</i> , 2022, 13, .	1.1	8
4	The role of plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. <i>Clinical Rheumatology</i> , 2021, 40, 1447-1456.	1.0	9
5	Demyelination with autoimmune features: a distinct clinical entity? Results from a longitudinal cohort. <i>Rheumatology</i> , 2021, 60, 4166-4174.	0.9	6
6	Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 758-766.	0.5	50
7	Treatment of neuropsychiatric systemic lupus erythematosus: clinical challenges and future perspectives. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 317-329.	1.3	10
8	Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1175-1182.	0.5	9
9	Transcriptome reprogramming and myeloid skewing in haematopoietic stem and progenitor cells in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 242-253.	0.5	44
10	Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease. <i>Lupus Science and Medicine</i> , 2020, 7, e000394.	1.1	18
11	Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1387-1393.	1.6	16
12	Evolving phenotype of systemic lupus erythematosus in Caucasians: low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the "Attikon"™ cohort. <i>Lupus</i> , 2020, 29, 514-522.	0.8	31
13	In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 232-241.	0.5	71
14	Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention. <i>Current Vascular Pharmacology</i> , 2020, 18, 549-565.	0.8	61
15	Suspected systemic rheumatic diseases in patients presenting with cytopenias. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101425.	1.4	5
16	Update on the pathogenesis of central nervous system lupus. <i>Current Opinion in Rheumatology</i> , 2019, 31, 669-677.	2.0	22
17	Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management. <i>Mediterranean Journal of Rheumatology</i> , 2019, 30, 7-15.	0.3	33